Abiomed Inc. was awarded an expanded PMA to treat heart failure linked to cardiomyopathy resulting in cardiogenic shock, adding to the April 2016 indication for acute myocardial infarction (AMI), cardiogenic shock, and post-cardiotomy cardiogenic shock. The expansion is applied to Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps, which are temporary ventricular support devices for short use in order to alleviate ventricle strain and provide time for recovery and functional assessment.